|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
zum B, üschenfelde CM, Hermann C, Schmidt
B, Peschel C and Bernhard H: Antihuman epidermal growth factor
receptor 2 (HER2) monoclonal antibody trastuzumab enhances
cytolytic activity of class I-restricted HER2-specific T
lymphocytes against HER2-overexpressing tumor cells. Cancer Res.
62:2244–2247. 2002.PubMed/NCBI
|
|
3
|
Imai C, Iwamoto S and Campana D: Genetic
modification of primary natural killer cells overcomes inhibitory
signals and induces specific killing of leukemic cells. Blood.
106:376–383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang M, Daniel S, Huang Y, Chancey C,
Huang Q, Lei YF, Grinev A, Mostowski H, Rios M and Dayton A:
Anti-West Nile virus activity of in vitro expanded human primary
natural killer cells. BMC Immunol. 11:32010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosenberg SA, Lotze MT, Muul LM, Leitman
S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E,
Vetto JT, et al: Observations on the systemic administration of
autologous lymphokine-activated killer cells and recombinant
interleukin-2 to patients with metastatic cancer. N Engl J Med.
313:1485–1492. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoechst B, Ormandy LA, Ballmaier M, Lehner
F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of
myeloid-derived suppressor cells in hepatocellular carcinoma
patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology.
135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sato E, Olson SH, Ahn J, Bundy B,
Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone
C, et al: Intraepithelial CD8+ tumor-infiltrating
lymphocytes and a high CD8+/regulatory T cell ratio are
associated with favorable prognosis in ovarian cancer. Proc Natl
Acad Sci USA. 102:pp. 18538–18543. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu J, Li H, Cao S, Zhang X, Yu J, Qi J,
An X, Yu W, Ren X and Hao X: Maintenance therapy with autologous
cytokine-induced killer cells in patients with advanced epithelial
ovarian cancer after first-line treatment. J Immunother.
37:115–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Orange JS: Formation and function of the
lytic NK-cell immunological synapse. Nat Rev Immunol. 8:713–725.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zompi S and Colucci F: Anatomy of a
murder-signal transduction pathways leading to activation of
natural killer cells. Immunol Lett. 97:31–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Biron CA, Nguyen KB, Pien GC, Cousens LP
and Salazar-Mather TP: Natural killer cells in antiviral defense:
Function and regulation by innate cytokines. Annu Rev Immunol.
17:189–220. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moretta L, Bottino C, Pende D, Vitale M,
Mingari MC and Moretta A: Human natural killer cells: Molecular
mechanisms controlling NK cell activation and tumor cell lysis.
Immunol Lett. 100:7–13. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ravetch JV and Bolland S: IgG Fc
receptors. Annu Rev Immunol. 19:275–290. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farag SS, VanDeusen JB, Fehniger TA and
Caligiuri MA: Biology and clinical impact of human natural killer
cells. Int J Hematol. 78:7–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alderson KL and Sondel PM: Clinical cancer
therapy by NK cells via antibody-dependent cell-mediated
cytotoxicity. J Biomed Biotechnol. 2011:3791232011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miller JS, Soignier Y,
Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna
D, Le C, Defor TE, Burns LJ, et al: Successful adoptive transfer
and in vivo expansion of human haploidentical NK cells in patients
with cancer. Blood. 105:3051–3057. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rubnitz JE, Inaba H, Ribeiro RC, Pounds S,
Rooney B, Bell T, Pui CH and Leung W: NKAML: A pilot study to
determine the safety and feasibility of haploidentical natural
killer cell transplantation in childhood acute myeloid leukemia. J
Clin Oncol. 28:955–959. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curti A, Ruggeri L, D'Addio A, Bontadini
A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli
G, et al: Successful transfer of alloreactive haploidentical KIR
ligand-mismatched natural killer cells after infusion in elderly
high risk acute myeloid leukemia patients. Blood. 118:3273–3279.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iliopoulou EG, Kountourakis P, Karamouzis
MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M
and Perez SA: A phase I trial of adoptive transfer of allogeneic
natural killer cells in patients with advanced non-small cell lung
cancer. Cancer Immunol Immunother. 59:1781–1789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geller MA, Cooley S, Judson PL, Ghebre R,
Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A,
Curtsinger J, McKenna D, et al: A phase II study of allogeneic
natural killer cell therapy to treat patients with recurrent
ovarian and breast cancer. Cytotherapy. 13:98–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
